自2024年国家卫生健康委等十六部门启动“体重管理年”三年行动计划以来,“减重”就成为一个热门的大众话题。在众多减重手段中,最早用于二型糖尿病治疗的GLP-1药物,近两年因减重效果在全球走红,诺和诺德的司美格鲁肽、礼来的替尔泊肽是其中的代表。 11月5日至10日,第八届中国国际进口博览会在上海举办,丹麦制药巨头诺和诺德、美国知名药企礼来均携旗下明星GLP-1减肥药亮相。司美格鲁肽和替尔泊肽是进...
Source Link自2024年国家卫生健康委等十六部门启动“体重管理年”三年行动计划以来,“减重”就成为一个热门的大众话题。在众多减重手段中,最早用于二型糖尿病治疗的GLP-1药物,近两年因减重效果在全球走红,诺和诺德的司美格鲁肽、礼来的替尔泊肽是其中的代表。 11月5日至10日,第八届中国国际进口博览会在上海举办,丹麦制药巨头诺和诺德、美国知名药企礼来均携旗下明星GLP-1减肥药亮相。司美格鲁肽和替尔泊肽是进...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.